Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia.
- Author:
Tao SUI
1
;
Lei ZHANG
;
Ze-ping ZHOU
;
Feng XUE
;
Jing GE
;
Ren-chi YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antibodies, Monoclonal; administration & dosage; therapeutic use; Antibodies, Monoclonal, Murine-Derived; administration & dosage; therapeutic use; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Rituximab; Thrombocytopenia; drug therapy; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2011;32(9):583-586
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of two different regimens of low doses rituximab for the treatment of adult patients with immune thrombocytopenia (ITP).
METHODSFifty-one patients were enrolled in this study and was non-randomly assigned to receive 100 mg rituximab weekly for 4 weeks (group A, 31 cases) or a single dose of 375 mg/m2 rituximab (group B, 20 cases).
RESULTSFor group A: Overall and complete response (OR and CR) rates were 58% and 29% , respectively. In responders, the median time to response was 42 (10 -101) days, with a median follow-up time of 15 (10 - 16) months, 3 of 18 responders (17%) relapsed. For group B: OR and CR rates were 50% and 35% , respectively. In responders, the median time to response was 35 (18 - 108) days, with a median follow-up time of 13 (6 -17) months, 1 of 9 responders (11%) relapsed. No significant difference in the OR, CR, the relapse rate and relapse free survival was observed in patients between the two groups.
CONCLUSIONThe low dose rituximab regimen (100 mg weekly for 4 weeks or a single close of 375 mg/m2) may be a useful alternative therapy in patients with ITP.
